Expand all sections

Aprocitentan

Extended indication Resistant hypertension
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Aprocitentan
Domain Cardiovascular diseases
Reason of inclusion New medicine (specialité)
Main indication Antithrombotic medications
Extended indication Resistant hypertension
Manufacturer Idorsia Pharmaceuticals
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Extramural (GVS)
Additional remarks Endothelin receptor antagonist.

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
ATMP No
Submission date February 2023
Expected Registration March 2024
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet
Dosage per administration 12,5mg - 25mg
References NCT03541174

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.